statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for...

Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Corcept Therapeutics completes enrollment in Phase 3 GRADIENT trial

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 25,953 shares of the stock in a transaction on Wednesday, March 27th. The shares were sold at an average...

Sean Maduck Sells 25,953 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Evanson Asset Management LLC lessened its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 10.7% in the fourth quarter, according to its most recent disclosure with...

Evanson Asset Management LLC Sells 3,706 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

A month has gone by since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have lost about 0.6% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

This price move could be a signal that CORT may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Corcept Therapeutics (CORT, $25.36) price may drop as it broke higher Bollinger Band on Mar 27, 2024

Corcept Therapeutics Incorporated (NASDAQ:CORT  Get Free Report) insider Sean Maduck sold 17,219 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $430,475.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT  Get Free Report) has earned a consensus recommendation of Moderate Buy from the six research firms that are presently covering...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $33.79 Average Price Target from Analysts

Corcept Therapeutics management to meet with Truist

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Volume	820,551.00
52-Wk High	$34.28
52-Wk Low	$20.84

CORT Corcept Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals